Table 2.

Clinical and Molecular Characteristics of Seven Patients With Choroidal Metastases

Patients	Patient #1	Patient #2	Patient #3	Patient #4	Patient #5	Patient #6	Patient #7
Sex	Male	Female	Female	Female	Female	Female	Male
Ethnic group	Moroccan	Caucasian	Caucasian	Caucasian	Chinese	Guinean	Moroccan
Age-ranges at the time of diagnosis	60–65 years	60–65 years	45–50 years	50–55 years	45–50 years	50–55 years	50–55 years
History of smoking	12 pack-years, quitted 18 years ago	27 pack-years, quitted 27 years ago	No	20 pack-years (active)	No	No	30 pack-years (active)
TNM stage at time of diagnosis (8th classification)	cT3N0M1c	cT1cN3M1c	cT4N3M1c	cT4N3M1c	cT2N3M1c	cT3N2M1c	cT4N2M1c
EGFR mutation(s) at time of diagnosis	Deletion of exon 19 c2236_2250del	Deletion of exon 19 c2240_2257del	Complex mutation of exon 21 Leu833Val His835Leu	Mutation of exon 21 L858R Mutation of exon 20 T790M (AF = 11.6%)	Mutation of exon 21 L858R	Mutation of exon 21 Leu858R	Deletion of exon 19 c2235_2249del
Mutation TP53	No	Exon 5	No	Exon 5	Exon 7	No	Exon 7
IHC Rb	Positive	Negative	Positive	Positive	Negative	Negative	Negative
Anti-EGFR treatments (number of lines)	1	3	2	3	1	1	3
Anti-EGFR TKIs	Afatinib L1	Afatinib L1 Osimertinib L3 Osimertinib L5	Afatinib L6 Osimertinib L7	Erlotinib L1 Osimertinib L2 Osimertinib L5	Erlotinib L1	Erlotinib L2	Erlotinib L1 Osimertinib L2 Afatinib L4
Carcinomatous meningitis during disease course	No	Confirmed by cytology	High MRI probability	High MRI probability	No	Confirmed by cytology	High MRI probability
Transformation in SCLC during disease course	No	No	No	No	Yes	No	No
Alive on Aug. 2020	Yes	No	No	No	No	No	No
Follow-up from diagnosis	25 months	Death at 17 months	Death at 23 months	Death at 27 months	Death at 6 months	Death at 2 months	Death at 36 months

EGFR epidermal growth factor receptor, IHC immunohistochemistry, TKI tyrosine kinase inhibitor, SCLC small cell lung cancer, MRI magnetic resonance imaging, AF allelic frequency